Answers are grounded in this paper and cite their sources.
WHO targets for elimination of viral hepatitis as a public health threat require substantial increases in access to testing and treatment worldwide.1 Although many challenges remain, advances in hepatitis C treatment have given a critical impetus to elimination efforts. Replacing interferon-based therapy with direct-acting antivirals allows treatment that is shorter in duration, more effective, less toxic and, crucially, simpler for patients to take and providers to deliver. No longer does access to specialist care need to hold back more widespread access to hepatitis C treatment in the range of settings where it is needed most.
No takes yet. Share an insight, caveat, or question.
Graham Cooke (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: